CASI Pharmaceuticals Inc
CASI
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.33M
Close$
$3.55
2259.1% upside
Current Fair Value
2259.1% upsideUndervalued by 2259.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.33 Million |
|---|---|
| Enterprise Value | $16.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.56 |
| Beta | 0.89 |
| Outstanding Shares | 16,049,326 |
Return
| Return on Equity | 172.70% |
|---|---|
| Return on Assets | -201.86% |
| Return on Invested Capital | 284.36% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | -0.14 |
| Price to Sales | 0.15 |
| Price to Book Ratio | -0.08 |
| Enterprise Value to Revenue | 0.61 |
| Enterprise Value to EBIT | -0.39 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.14 |
| Debt to Equity | -0.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.83%▼ 8.98% |
|---|---|
| Total Invested | $1.21M▼ 72.05% |
| Investors Holding | 17▼ 4.00% |
ESG Score
No data
About CASI Pharmaceuticals Inc
CEO: Wei-Wu He CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on...